Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy

Introduction: Approximately 30% of patients with primary membranous nephropathy (MN) and nephrotic syndrome (NS) fail rituximab treatment through mechanisms that could be overcome by the human IgG1 monoclonal anti-CD38 antibody, felzartamab. Methods: In this prospective, single-arm, single-center, o...

全面介紹

書目詳細資料

Principais autores:	Matias Trillini, Federica Casiraghi, Alessia Gennarini, Valentina Portalupi, Maddalena Marasà, Manuel Alfredo Podestà, Silvia Prandini, Silvia Nozza, Marta Todeschini, Francesco Pecoraro, Marilena Mister, Fabiola Carrara, Nadia Stucchi, Tobia Peracchi, Diego Fidone, Alessandro Villa, Nadia Rubis, Olimpia Diadei, Davide Martinetti, Giuseppe Remuzzi, Piero Ruggenenti
格式:	Artigo
語言:	Inglês
出版:	Elsevier 2026-06-01
叢編:	Kidney International Reports
主題:	anti-CD38 antibodies felzartamab membranous nephropathy nephrotic syndrome rituximab
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S2468024926027002
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!